News
PRTA
62.62
+7.74%
4.50
BRIEF-Prothena Announces Achievement Of $40 Mln Clinical Milestone Payment From Novo Nordisk For Prx004/Nnc6019
Reuters · 11/21 23:29
Novo Nordisk Agrees to $40 Million Milestone Milestone Payment to Prothena
Novo Nordisk Agrees to $40 Million Milestone Milestone Payment to Prothena
MT Newswires · 11/21 17:42
One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments
Marketwatch.com · 11/14 19:34
Cassava, Biogen lead Alzheimer's stocks higher following Roche's gantenerumab setback
Seekingalpha · 11/14 16:59
Hasbro, DENTSPLY SIRONA, Prothena Corporation among premarket losers' pack
Seekingalpha · 11/14 13:32
UPDATE 1-Roche says Alzheimer's drug fails to meet goal in trial
Reuters · 11/14 06:16
What 4 Analyst Ratings Have To Say About Prothena Corp
Benzinga · 11/04 14:28
Prothena drops 9% as RBC Capital Markets downgrades citing valuation
Seekingalpha · 11/04 14:06
RBC Capital Downgrades Prothena Corp to Sector Perform, Raises Price Target to $55
Benzinga · 11/04 10:16
--RBC Downgrades Prothena to Sector Perform From Outperform, Citing Valuation, Lifts Price Target to $55 From $52, Keeps Speculative Risk Qualifer
--RBC Downgrades Prothena to Sector Perform From Outperform, Citing Valuation, Lifts Price Target to $55 From $52, Keeps Speculative Risk Qualifer
MT Newswires · 11/04 08:16
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -212.90% and 94.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03 23:15
Recap: Prothena Corp Q3 Earnings
Benzinga · 11/03 21:09
Prothena Corp Q3 EPS $(0.97) Misses $(0.53) Estimate, Sales $1.52M Miss $22.06M Estimate
Benzinga · 11/03 20:22
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
DUBLIN, November 03, 2022--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the third q...
Business Wire · 11/03 20:05
-- Earnings Flash (PRTA) PROTHENA CORPORATION Reports Q3 Revenue $1.5M
-- Earnings Flash (PRTA) PROTHENA CORPORATION Reports Q3 Revenue $1.5M
MT Newswires · 11/03 16:22
Prothena To Present Data On Survival Benefit Observed In Completed Phase 3 Study Of Drug Candidate Birtamimab In Patients With Mayo Stage IV AL Amyloidosis At The ASH 2022 Meeting
Benzinga · 11/03 13:33
Earnings Preview: Prothena Corp
Benzinga · 11/02 18:40
Insider Sell: Prothena
Insider Sell: Prothena
MT Newswires · 10/31 07:40
As Small Caps Rally, These 3 Finance High-Yielders Could Have Further Upside
Benzinga · 10/28 21:24
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
DUBLIN, Ireland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it ...
GlobeNewswire · 10/27 20:05
More
Webull provides a variety of real-time PRTA stock news. You can receive the latest news about Prothena through multiple platforms. This information may help you make smarter investment decisions.
About PRTA
Prothena Corporation Public Limited Company is a late-stage clinical company engaged in the protein dysregulation and a pipeline of investigational therapies for rare peripheral amyloid and neurodegenerative diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company is also advancing several discovery and preclinical-stage programs for neurological diseases with unmet medical needs such as AD and amyotrophic lateral sclerosis (ALS). The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis. The Company's pipeline includes AL Amyloidosis & Birtamimab, Parkinson’s Disease & Prasinezumab, Transthyretin amyloidosis (ATTR) & PRX004, Alzheimer’s Disease and Pioneering Neuroscience.